Skip to main content
U2BIO CO., LTD. logo

U2BIO CO., LTD. — Investor Relations & Filings

Ticker · 221800 ISIN · KR7221800006 KO Human health and social work activities
Open in API
Filings indexed 227 across all filing types
Latest filing 2026-02-13 Major Shareholding Noti…
Country KR South Korea
Listing KO 221800

About U2BIO CO., LTD.

https://www.u2bio.co.kr/eng/main.do

U2BIO CO., LTD. is a healthcare technology company specializing in the integration of biotechnology (BT) and information technology (IT). The company provides a range of in vitro diagnostic services, including clinical laboratory tests and molecular diagnostics. Concurrently, it develops and offers digital healthcare solutions and medical IT services tailored for medical institutions such as hospitals and clinics. U2BIO focuses on delivering personalized healthcare services based on scientific data to support medical professionals and improve patient health outcomes.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by a major shareholder (Lee Jaewoong) of U2Bio, including specific transaction dates, quantities, and counterparties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-02-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is a mandatory disclosure when an insider or major shareholder changes their stake in the company. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider trades and changes in ownership by company directors and major shareholders.
2026-02-13 Korean
주요사항보고서(회사분할결정)
Share Issue/Capital Change Classification · 98% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate spin-off (회사분할 결정) filed by U2Bio Co., Ltd. with the Korean financial authorities. It details the plan for a simple/physical spin-off (물적분할), including the division of business units, financial implications, shareholder appraisal rights, and the spin-off schedule. This type of regulatory filing concerning corporate restructuring and spin-offs is classified under 'Regulatory Filings' (RNS) as it is a formal disclosure of a significant corporate event.
2026-02-09 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for U2Bio. It outlines the date, location, and specific agenda items (proposals) for the upcoming Annual General Meeting, including financial statement approval, dividend decisions, and director appointments. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2026-02-09 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from U2Bio regarding a decision on cash dividends ('현금ㆍ현물배당 결정'). It specifies the dividend amount per share, the total dividend amount, the record date, and the expected date of the general meeting for approval. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2026-02-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (U2Bio) disclosing a significant change in financial structure (revenue or profit/loss fluctuation of 15% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for preliminary financial results before the final audit report is issued. Since it provides key financial highlights and performance metrics for the fiscal year, it falls under the Earnings Release (ER) category, as it serves as the initial announcement of financial results.
2026-02-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.